Chronic inflammation is one of the main hallmarks of cancer cachexia, and targeting inflammatory cytokines may alleviate the symptoms of cancer cachexia.13 MABp1, an antibody targeting IL-1α, resulted in a significant reduction in systemic inflammation and thrombocytosis in CRC patients but did not improve cancer cachexia symptoms. The gene discussed is IL1A; the disease is cancer.